Pharmathen Sustainability Profile
Pharmathen S.A., a leading pharmaceutical company headquartered in Greece (GR), has established itself as a key player in the global healthcare industry since its founding in 1975. With a strong presence in Europe, the Middle East, and Africa, Pharmathen focuses on the development, manufacturing, and marketing of innovative generic and specialty pharmaceuticals. The company is renowned for its advanced drug delivery systems and high-quality formulations, which cater to a diverse range of therapeutic areas. Notable achievements include significant investments in research and development, positioning Pharmathen as a trusted partner for both healthcare professionals and patients. With a commitment to excellence and a robust portfolio of products, Pharmathen continues to enhance its market position and contribute to the advancement of global health.
DitchCarbon Score
How does Pharmathen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmathen's score of 42 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pharmathen's reported carbon emissions
In 2024, Pharmathen reported total greenhouse gas emissions of approximately 174,000,000 kg CO2e, comprising 7,247,000 kg CO2e from Scope 1, 8,849,000 kg CO2e from Scope 2, and a significant 155,577,000 kg CO2e from Scope 3 emissions. The previous year, 2023, saw total emissions of about 13,736,000 kg CO2e from Scope 1 and 2 combined, with Scope 1 emissions at 6,390,000 kg CO2e and Scope 2 emissions at 8,125,000 kg CO2e. Notably, Pharmathen achieved a 9% reduction in total GHG emissions in 2023 compared to the base year 2022, attributed to increased use of renewable energy sources. Pharmathen has set ambitious climate commitments, targeting a 45% reduction in GHG emissions by 2030, with a focus on enhancing renewable energy usage and improving energy efficiency across its operations. The company has also formalised its pledge to achieve net-zero emissions by 2050, encompassing both Scope 1 and Scope 2 emissions. These commitments reflect Pharmathen's proactive approach to sustainability and its alignment with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 5,808,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 9,300,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 000,000,000 |
How Carbon Intensive is Pharmathen's Industry?
How Carbon Intensive is Pharmathen's Location?
Pharmathen's Scope 3 Categories Breakdown
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 84% of Scope 3 emissions.
Top Scope 3 Categories
Pharmathen's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pharmathen has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
